Related Experiment Video
Updated: Dec 10, 2025
Printed Glycan Array: A Sensitive Technique for the Analysis of the Repertoire of Circulating Anti-carbohydrate Antibodies in Small Animals
Published on: February 14, 2019
Antibodies Against Glycoprotein 2 Are Specific Biomarkers for Pediatric Crohn's Disease
Michael Shpoliansky1,2, Dirk Roggenbuck3,4, Marina Pinsker1
1Pediatric Gastroenterology Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.
Insights
Anti-glycoprotein 2 (anti-GP2) shows high specificity for pediatric Crohn's disease (CD) in children, differentiating it from ulcerative colitis (UC). While not excluding CD, positive anti-GP2 levels correlate with disease activity.
Area of Science:
- Pediatric gastroenterology
- Immunology
- Biomarker discovery
Background:
- Differentiating pediatric Crohn's disease (CD) from ulcerative colitis (UC) is clinically important.
- Anti-glycoprotein 2 (anti-GP2) is a specific serological marker for CD in adults.
- The utility of anti-GP2 in pediatric CD requires further investigation.
Purpose of the Study:
- To evaluate anti-GP2 and GP2 as biomarkers for pediatric CD.
- To assess the correlation of anti-GP2 with disease activity in pediatric CD.
- To determine the diagnostic accuracy of anti-GP2 in distinguishing pediatric CD from UC.
Main Methods:
- Serum samples from pediatric patients with CD, UC, and controls were analyzed using ELISA.
- Levels of anti-GP2 IgG, IgA, and GP2 were measured.
- Results were correlated with demographic and clinical data, including disease activity.
Main Results:
- Anti-GP2 levels were significantly elevated in pediatric CD patients compared to UC patients and controls.
- Anti-GP2 demonstrated high specificity (98.7% for IgG, 90.0% for IgA) but low sensitivity (42.0% for IgG, 35.5% for IgA).
- Positive anti-GP2 correlated with disease activity and decreased after successful treatment; IgA anti-GP2 was associated with ileo-colonic involvement and younger age.
Conclusions:
- Anti-GP2 is a highly associated marker for pediatric CD, though a negative result does not rule out the disease.
- The findings support the potential of anti-GP2 in diagnosing pediatric CD.
- Further research is needed to explore the role of anti-GP2 in risk stratification for pediatric CD.
Background:
Serological markers can assist in accurate differentiation between Crohn's disease (CD) and ulcerative colitis (UC). One such marker is anti-glycoprotein 2 (anti-GP2) which was shown to be a specific marker for CD in adult patients. The aim of our study was to assess the utility of anti-GP2 and GP2 as biomarkers for pediatric CD, and determine whether they correlate with disease activity.
Methods:
Serum samples were tested by ELISA for anti-GP2 isoform 4 IgG and IgA, and also for GP2. Results were correlated with demographic and clinical data.
Results:
The cohort consisted of 53 pediatric patients with CD, 42 with UC, and 53 controls. Levels of anti-GP2 were significantly increased in pediatric patients with CD in comparison with patients with UC, and control subjects, with high positive predictive value for both IgG and IgA (97.9% and 82.6%, respectively). While specificity of anti-GP2 IgG and IgA was very high (98.7% and 90.0%, respectively), sensitivity was low (42.0% and 35.5% for IgG and IgA, respectively). In CD, anti-GP2 correlated with disease activity, and decreased in treatment-naïve patients following successful induction therapy. A higher IgA anti-GP2 was also demonstrated in patients with ileo-colonic involvement, and was associated with a younger age. Finally, positive GP2 level was identified in only 1/211 serum samples.
Conclusions:
A positive anti-GP2 level is highly associated with CD, while a negative result does not exclude CD. Additional studies are required to determine whether these markers can be used in pediatric patients with CD for risk stratification.
More Related Videos
10:27Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
Published on: December 15, 2011
09:12A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
Published on: June 15, 2018
Related Concept Videos
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:17Gastritis-II: Pathophysiology
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...